Kiora Pharmaceuticals, Inc.
KPRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.09 | -0.35 | 0.02 | -0.01 |
| FCF Yield | -10.68% | -33.39% | -21.30% | -22.29% |
| EV / EBITDA | -11.80 | -4.83 | -4.42 | -2.57 |
| Quality | ||||
| ROIC | 0.40% | -7.88% | -8.09% | -8.41% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -47.49 | 1.77 | 1.23 | 0.53 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | 2,519,742.10% |
| Free Cash Flow Growth | 66.80% | -41.84% | -22.51% | -339.91% |
| Safety | ||||
| Net Debt / EBITDA | 8.83 | 0.27 | 1.76 | 1.56 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -119.59 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -568.39 | 0.00 | 0.00 | 0.00 |